uniQure N.V.
QURENasdaq
$40.25
↑ +2.3%Jul 17 close · end-of-day
Price
1Y↑ +179.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.5B
Enterprise Value
$2.4B
P/E
—
P/S
139.6
P/B
16.9
EV/EBITDA
—
PEG
—
FCF Yield
-6.8%
Dividend Yield
—
Revenue (TTM)
$18.1M
Net Income (TTM)
-$208.9M
Free Cash Flow (TTM)
-$172.6M
Gross Margin
—
Operating Margin
-1059.7%
Net Margin
-1154.6%
ROE
-139.9%
ROIC
-255.5%
Debt / Equity
0.3
Net Cash
$90.1M
Return 1Y
+164.8%
Company profile
uniQure N.V. engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in clinical study for Huntington's disease.
- CEO
- Matthew C. Kapusta
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 500
- Website
- uniqure.com
Management & directors
- Kapusta Matthew CCEO, Managing Director
- Abi-Saab WalidChief Medical Officer
- Potts JeannetteChief Legal Officer
- O'Keefe KylieChief Customer & Strat Officer
- Klemt ChristianChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
QURE Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$3.6M↑ +127.3%
Diluted EPS-$0.85↑ +3.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $37.5M | $524.0M | $106.5M | $15.8M | $27.1M | $16.1M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$125.4M | $310.6M | -$143.2M | -$282.9M | -$184.3M | -$185.3M |
| Net income | — | $329.6M | -$126.8M | -$308.5M | -$239.6M | -$199.0M |
| Diluted EPS | -$2.81 | $7.04 | -$2.71 | -$6.47 | -$4.92 | -$3.46 |
| Operating cash flow | -$134.8M | $288.0M | -$145.1M | -$145.9M | -$182.7M | -$178.0M |
| Free cash flow | -$142.1M | $270.5M | -$162.7M | -$153.1M | -$186.1M | -$178.4M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -334.3% | 59.3% | -134.4% | -1785.5% | -679.6% | -1151.4% |
| Net margin | — | 62.9% | -119.1% | -1947.2% | -883.5% | -1236.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.1M | $2.3M | $5.2M | $1.6M | $5.3M | $3.7M | $5.6M | $3.6M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$44.0M | -$40.2M | -$45.8M | -$39.3M | -$43.9M | -$51.0M | -$51.1M | -$45.7M |
| Net income | -$56.3M | -$44.4M | — | -$43.6M | -$37.7M | -$80.5M | -$37.1M | -$53.5M |
| Diluted EPS | -$1.16 | -$0.91 | -$1.49 | -$0.82 | -$0.69 | -$1.38 | -$0.57 | -$0.85 |
| Operating cash flow | -$32.7M | -$36.6M | -$52.8M | -$44.1M | -$39.9M | -$16.4M | -$77.6M | -$38.2M |
| Free cash flow | -$33.3M | -$37.0M | -$52.9M | -$44.2M | -$40.2M | -$16.5M | -$77.7M | -$38.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -395.6% | -1759.0% | -877.8% | -2510.0% | -833.6% | -1379.0% | -918.1% | -1283.5% |
| Net margin | -506.0% | -1940.4% | — | -2784.7% | -716.8% | -2175.9% | -666.6% | -1502.9% |
Company news
Jul 18, 2026
Jul 17, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-02 | Kapusta Matthew C· CEO, Managing Director | Option exercise | 21,082 | $19.39 | $408,779.98 | filing |
| 2026-07-02 | Kapusta Matthew C· CEO, Managing Director | Sale | 9,200 | $44.43 | $408,756.00 | filing |
| 2026-07-02 | Kapusta Matthew C· CEO, Managing Director | Sale | 7,600 | $45.89 | $348,764.00 | filing |
| 2026-07-02 | Kapusta Matthew C· CEO, Managing Director | Sale | 4,282 | $45.43 | $194,531.26 | filing |
| 2026-06-30 | Abi-Saab Walid· Chief Medical Officer | Sale | 20,000 | $46.40 | $928,000.00 | filing |
| 2026-06-30 | Kaye Jack | Sale | 17,060 | $46.43 | $792,095.80 | filing |
| 2026-06-30 | Abi-Saab Walid· Chief Medical Officer | Sale | 10,000 | $46.46 | $464,600.00 | filing |
| 2026-06-30 | Kaye Jack | Option exercise | 17,060 | $20.18 | $344,270.80 | filing |
| 2026-06-30 | Kaye Jack | Sale | 4,107 | $46.49 | $190,934.43 | filing |
| 2026-06-30 | Kaye Jack | Option exercise | 4,107 | $37.00 | $151,959.00 | filing |
| 2026-06-30 | Abi-Saab Walid· Chief Medical Officer | Option exercise | 10,000 | $5.59 | $55,900.00 | filing |
| 2026-06-26 | Abi-Saab Walid· Chief Medical Officer | Sale | 1,434 | $46.86 | $67,197.24 | filing |
| 2026-06-25 | Kapusta Matthew C· CEO, Managing Director | Sale | 28,716 | $50.02 | $1.4M | filing |
| 2026-06-25 | Kapusta Matthew C· CEO, Managing Director | Option exercise | 28,716 | $31.71 | $910,584.36 | filing |
| 2026-06-24 | Kapusta Matthew C· CEO, Managing Director | Sale | 6,696 | $50.00 | $334,800.00 | filing |
| 2026-06-24 | Kapusta Matthew C· CEO, Managing Director | Option exercise | 4,128 | $31.71 | $130,898.88 | filing |
| 2026-06-18 | Kapusta Matthew C· CEO, Managing Director | Sale | 37,015 | $50.00 | $1.9M | filing |
| 2026-06-18 | Kapusta Matthew C· CEO, Managing Director | Sale | 4,656 | $50.00 | $232,800.00 | filing |
| 2026-06-18 | Kapusta Matthew C· CEO, Managing Director | Option exercise | 4,656 | $31.71 | $147,641.76 | filing |
| 2026-06-17 | Kapusta Matthew C· CEO, Managing Director | Sale | 56,929 | $43.43 | $2.5M | filing |
| 2026-06-17 | Kapusta Matthew C· CEO, Managing Director | Sale | 33,334 | $45.01 | $1.5M | filing |
| 2026-06-17 | Kapusta Matthew C· CEO, Managing Director | Sale | 32,581 | $45.02 | $1.5M | filing |
| 2026-06-17 | Kapusta Matthew C· CEO, Managing Director | Option exercise | 62,581 | $19.39 | $1.2M | filing |
| 2026-06-17 | Kapusta Matthew C· CEO, Managing Director | Sale | 23,977 | $42.61 | $1.0M | filing |
| 2026-06-17 | Kapusta Matthew C· CEO, Managing Director | Sale | 11,585 | $48.65 | $563,610.25 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.